Non-Hodgkin Lymphoma


lymphatic-system

Non-Hodgkin Lymphomas (NHL) are a heterogeneous group of disorders involving malignant monoclonal proliferation of lymphoid cells in lymphoreticular sites, including lymph nodes, bone marrow, the spleen, the liver, and the GI tract.

Most Non-Hodgkin lymphomas (NHL) are B-cell neoplasms though occasionally they are of T-cell lineage.

These tumors may result from chromosomal translocations, infections, environmental factors, immunodeficiency states, and chronic inflammation.

Clinical features:

Non-Hodgkin Lymphoma occurs mainly in the elderly, although some cases occur in childhood.

Most patients have widespread painless and slowly progressive lymphadenopathy at presentation (cf: Hodgkin’s Disease).

Non-Hodgkin Lymphoma

Hepatosplenomegaly is common.

Patients with less aggressive disease often have no symptoms, whereas those with aggressive disease tend to have B symptoms ((unexplained weight loss >10% of total body weight within the past 6 months, unexplained fever >38º C, or drenching night sweats).

Extranodal involvement: More than one-third of patients; most common sites are GI/GU tracts (including Waldeyer ring), skin, bone marrow, sinuses, thyroid, CNS.

Bone marrow involvement: May be associated with cytopenias and fatigue/weakness. More common in advanced-stage disease.

Two problems are common in NHL but rare in Hodgkin lymphoma: Congestion and oedema of the face and neck from pressure on the superior vena cava (superior vena cava or superior mediastinal syndrome) may occur. Also, ureters may be compressed by retroperitoneal or pelvic lymph nodes or both; this compression may interfere with urinary flow and cause secondary renal failure.

Clinical examination:

Examination in patients with low-grade lymphomas may demonstrate peripheral adenopathy, splenomegaly, and hepatomegaly.

Intermediate- and high-grade lymphomas may result in the following examination findings:

  • Rapidly growing and bulky lymphadenopathy
  • Splenomegaly
  • Hepatomegaly
  • Large abdominal mass: Usually in Burkitt lymphoma
  • Testicular mass
  • Skin lesions: Associated with cutaneous T-cell lymphoma (mycosis fungoides), anaplastic large-cell lymphoma, and angioimmunoblastic lymphoma

Investigations:

FBC, blood film, and DCT:

Anemia is not infrequent. Autoimmune hemolytic anemia may occur especially in low-grade lymphoma.

Neutropenia and thrombocytopenia occur if there is marrow failure, hypersplenism or an immune destruction.

Malignant cells are not usually detectable in the blood although a leukemic element may develop in the later stages.

Biochemistry & Immunology:

May show elevated LDH, calcium and uric acid levels, abnormal liver function tests. Serum beta2-microglobulin level may be elevated.

Hypoalbuminemia and hypergammaglobulinemia and M bands are not infrequent, though the M band level is usually small or moderate.

Viral serology:

  • HIV serology: Especially in patients with diffuse large cell immunoblastic or small noncleaved histologies.
  • Human T-cell lymphotropic virus-1 serology: For patients with adult T-cell leukemia/lymphoma.
  • Hepatitis B testing: In patients in whom rituximab therapy is planned because reactivation has been reported.

Bone marrow aspiration and biopsy:

A bone marrow biopsy shows infiltration with malignant lymphoid cells in approximately 20% cases. The infiltration is usually diffuse even in “nodular” disease, and often has a paratrabecular distribution.

small-lymphocytic-lymphoma-in-marrow

Excisional lymph node biopsy:

A lymph node biopsy is done if lymphadenopathy is confirmed on chest x-ray, CT, or PET. If only mediastinal nodes are enlarged, patients require CT-guided needle biopsy or mediastinoscopy.

Histologic criteria on biopsy include destruction of normal lymph node architecture and invasion of the capsule and adjacent fat by characteristic neoplastic cells.

LN biopsy-DLBCL

Immunophenotypic studies help to distinguish reactive from neoplastic lymphoid infiltrates, and lymphoid from nonlymphoid malignancies. They are of great value in identifying specific lymphoid subtypes and helping define prognosis and management; these studies also can be done on peripheral cells and bone marrow. Demonstration of the leucocyte common antigen CD45 by immunoperoxidase rules out metastatic cancer, which is often in the differential diagnosis of “undifferentiated” cancers.

Non-Hodgkin Lymphoma

Non-Hodgkin Lymphoma

The test for leucocyte common antigen, most surface marker studies, and gene rearrangement (to document B-cell or T-cell clonality) can be done on fixed tissues.

Cytogenetics and flow cytometry require fresh tissue.

All follicular lymphomas are of B-cell origin as are the majority of the diffuse NHL. T-cell NHL accounts for 10-15% of the diffuse NHL.

Non-Hodgkin Lymphoma

Although bcl -2 expression distinguishes follicular lymphoma from reactive follicular hyperplasia, bcl -1 expression strongly favors a diagnosis of mantle cell lymphoma.

Mantle cell lymphoma is a subtype of B-cell lymphomas which overexpress cyclin D1 due to a t(11:14) chromosomal translocation in the DNA.

CD30 expression is important for the recognition of anaplastic large cell lymphoma, and it can also be found in the majority of Hodgkin lymphomas.

Cytogenetic studies:

Cytogenetic abnormalities have been identified in Non-Hodgkin Lymphoma, and significant correlations among them and morphology, immunophenotyping, and parameters of clinical outcome have been recognized.

Various technological advances in cytogenetics combined with molecular approaches have greatly enhanced the ability to identify genetic abnormalities in any given tumor type.

Most follicular lymphomas have a t(14;18) translocation which results in high-level expression of the bcl-2 gene with protection of such cells from apoptosis.

Translocation t(11;14) is detected in 65% of mantle cell lymphoma cases by classic cytogenetic analysis, and in nearly all cases, by fluorescent in situ hybridization (FISH).

Rearrangements of the bcl-6 gene are common in diffuse large B-cell lymphoma (DLBCL) and t(8;14) translocations are frequent in small non-cleaved cell lymphomas e.g. Burkitt’s lymphoma, resulting in high-level expression of the proto-oncogene c-myc.

Lumbar puncture for CSF analysis:

lumbar puncture for CSF analysis is indicated in patients with the following conditions:

  • Diffuse aggressive NHL with bone marrow, epidural, testicular, paranasal sinus, or nasopharyngeal involvement, or 2 or more extranodal sites of disease.
  • High-grade lymphoblastic lymphoma.
  • High-grade small non-cleaved cell lymphomas e.g. Burkitt lymphoma.
  • HIV-related lymphoma.
  • Primary CNS lymphoma.
  • Neurologic signs and symptoms.

Imaging studies:

The following imaging studies should be obtained in a patient suspected of having Non-Hodgkin Lymphoma:

  • Chest radiography.
  • Echocardiogram & ECG: For patients being considered for treatment with anthracyclines.
  • CT scanning of the neck, chest, abdomen, and pelvis.

Non-Hodgkin Lymphoma

  • PET-CT scan: For baseline/staging in Aggressive NHL Including diffuse large B-cell lymphoma (DLBCL).
  • Testicular ultrasonography: For opposite testis in male patients with a testicular primary lesion.
  • MRI of brain/spinal cord: For suspected primary CNS lymphoma, lymphomatous meningitis, paraspinal lymphoma, or vertebral body involvement by lymphoma.
  • Bone scanning: Only in patients with bone pain, elevated alkaline phosphatase, or both.

Classification:

  • Many histological classifications are available illustrating their difficulty and deficiencies.
  • The classification used below (working formulation) is based on whether or not the tumor is diffuse or follicular, whether the cells are small or large and whether or not the nuclei are regular, cleaved or convoluted.
  • Reactive elements are in general less pronounced than in Hodgkin’s Disease.Non-Hodgkin Lymphoma
  • This classification does not take immunophenotype into account, although such studies do add additional information. One of the other weaknesses of this classification is that it does not take account of biological entities such as tumors of mucosa-associated lymphoid tissue (MALT).
  • The WHO classification is valuable because it incorporates immunophenotype, genotype, and cytogenetics, but numerous other systems exist.Non-Hodgkin Lymphoma
  • Non-Hodgkin Lymphomas are commonly also categorized as indolent or aggressive. Indolent lymphomas are slowly progressive and responsive to therapy but are not curable with standard approaches. Aggressive lymphomas are rapidly progressive but responsive to therapy and often curable.
  • In children, Non-Hodgkin Lymphoma is almost always aggressive. Follicular and other indolent lymphomas are very rare. The treatment of these aggressive lymphomas (Burkitt, diffuse large B cell, and lymphoblastic lymphoma) presents special concerns, including GI tract involvement (particularly in the terminal ileum); meningeal spread (requiring CSF prophylaxis or treatment); and other sites of involvement (eg, testes, brain). In addition, with these potentially curable lymphomas, treatment adverse effects as well as outcome must be considered, including late risks of secondary cancer, cardiorespiratory sequelae, fertility preservation, and developmental consequences. Current research is focused on these areas as well as on the molecular events and predictors of lymphoma in children.

Staging:

  • Although localized Non-Hodgkin Lymphoma does occur, the disease is typically disseminated when first recognized.
  • Staging procedures include CT of the chest, abdomen, and pelvis; PET; and bone marrow biopsy.

The final staging of NHL is similar to that of Hodgkin lymphoma and is based on clinical and pathologic findings.

Non-Hodgkin Lymphoma

Treatment:

Low-grade lymphomas although incurable at present, often progress very slowly, and treatment should only be given to relieve symptoms, or in a clinical trial.

In the intermediate and high-grade lymphomas patients are nearly all symptomatic and more aggressive therapy is justified as there is a chance of cure.

For the initial treatment of patients with high-grade lymphoma and patients with bulky disease, an inpatient setting is recommended in order to monitor for tumor lysis syndrome and to manage appropriately.

Localized disease (stages I and II):

Patients with indolent lymphomas rarely present with localized disease, but when they do, regional Radiation Therapy (RT) may offer long-term control. However, relapses may occur > 10 years after radiation therapy.

Non-Hodgkin Lymphoma

About half of patients with aggressive lymphomas present with localized disease, for which combination chemotherapy, with or without regional radiation, is usually curative.

Patients with lymphoblastic lymphomas or Burkitt lymphoma, even if apparently localized, must receive intensive combination chemotherapy with meningeal prophylaxis. Treatment may require maintenance chemotherapy, but cure is expected.

Advanced disease (stages III and IV):

For indolent lymphomas, treatment varies considerably. Follicular lymphoma comprises 70% of this group. Other entities in this group include small lymphocytic lymphoma (SLL), lymphoplasmacytoid lymphoma, and marginal zone lymphomas (MZL). A watch-and-wait approach or treatment with the B-cell specific monoclonal anti-CD20 antibody rituximab alone or combined with chemotherapy may be used. Criteria considered in selecting management options include age, general health, distribution of disease, tumor bulk, histology, and anticipated benefits of therapy. Single-agent treatment with chlorambucil or cyclophosphamide (with or without prednisone) is useful in elderly patients with significant comorbidities. However, only a few achieve remission; most achieve palliation.

Bendamustine plus rituximab has demonstrated efficacy for the first-line treatment of advanced follicular, indolent, and mantle cell lymphomas.

Current National Comprehensive Cancer Network guidelines give bendamustine plus rituximab, R-CHOP,  and R-CVP (rituximab, cyclophosphamide, vincristine, prednisone) category 1 recommendations for first-line therapy of follicular lymphoma.

Promising outcomes have been seen with the combination of lenalidomide plus rituximab for both rituximab-refractory and non–rituximab-refractory indolent NHL.

Bortezomib has also been used in patients with relapsed or refractory mantle cell lymphoma.

Maintenance therapy with rituximab after induction chemotherapy has been reported to prolong progression-free survival (PFS) in comparison with observation alone in patients with indolent lymphoma.

In patients with the aggressive B-cell lymphomas (e.g. diffuse large B-cell lymphoma), the standard drug combination is rituximab plus cyclophosphamide, hydroxydaunorubicin (doxorubicin), vincristine, and prednisone (R-CHOP). Currently, 6-8 cycles of R-CHOP chemotherapy is the standard of care in patients with advanced disease. Complete disease regression is expected in 70% of patients, depending on the International Prognostic Index (IPI) category.

Non-Hodgkin Lymphoma

More than 70% of complete responders are cured, and relapses > 2 years after end of treatment are rare.

Cure rates have improved with the use of R-CHOP, so autologous stem cell transplantation is reserved for patients with relapsed or refractory aggressive B-cell lymphomas, some younger patients with mantle cell lymphoma, and some patients with aggressive T-cell lymphomas.

Pixantrone (Pixuveri) is an effective aza-anthracenedione with reduced cardiotoxicity and significant antineoplastic activity which may represent a therapeutic option in relapsed/refractory non-Hodgkin B-cell lymphoma. Pixantrone, with its activity and favorable safety profile, could represent a promising agent for novel combination regimens e.g. pixantrone-rituximab regimen, aiming to improve progression-free survival.

CNS prophylaxis, usually with 4-6 injections of Methotrexate intrathecally, is recommended for patients with paranasal sinus, tonsillar or testicular involvement, diffuse small noncleaved cell or Burkitt lymphoma, or lymphoblastic lymphoma. CNS prophylaxis for bone marrow involvement is controversial.

Treatment of acute lymphoblastic lymphoma, a very aggressive form of NHL, is similar to acute lymphoblastic leukemia (ALL) therapy. Other subtypes of high-grade lymphomas are usually treated with more aggressive variations of CHOP chemotherapy, including the addition of high-dose methotrexate or other chemotherapy drugs and higher doses of cyclophosphamide.

Management of T-cell Lymphomas:

The treatment of T-cell lymphomas continues to be challenging. T-cell lymphomas are divided into 2 subgroups: cutaneous or systemic T-cell disorders.

Typically, cutaneous T-cell lymphomas (CTCL) are managed with topical agents and oral disease modifiers during the early stage of the disease. Systemic chemotherapy is usually incorporated late in the course of the disease with modest activity.

Systemic T-cell lymphomas represent a challenge to the practicing oncologist. Combination chemotherapy regimens – CHOP, CHOP plus etoposide, or gemcitabine-based regimens are treatment options. Alemtuzumab, Pralatrexate (Folotyn), Romidepsin (Istodax) and Belinostat (Beleodaq) are effective in selected cases.

Relapse:

The first relapse after initial chemotherapy could be treated with autologous stem cell transplantation. Patients usually should be 70 years or in equivalent health and have responsive disease, good performance status, and an adequate number of CD34+ stem cells (harvested from peripheral blood or bone marrow).

Consolidation myeloablative therapy may include chemotherapy with or without irradiation.

Posttreatment immunotherapy (eg, rituximab, vaccination, IL-2) is being studied.

An allogeneic transplant is the donation of stem cells from a compatible donor (brother, sister, matched unrelated donor, or umbilical cord blood). The stem cells have a 2-fold effect: reconstituting normal blood counts and providing a possible graft-vs-tumor effect.

In aggressive lymphoma, a cure may be expected in 30 to 50% of eligible patients undergoing myeloablative therapy and transplantation.

In indolent lymphomas, cure with autologous stem cell transplantation remains uncertain, although remission may be superior to that with secondary palliative therapy alone.

Reduced-intensity allogeneic transplantation is a potentially curative option in some patients with indolent lymphoma.

The mortality rate of patients undergoing myeloablative transplantation has decreased dramatically to 2 to 5% for most autologous procedures and to < 15% for most allogeneic procedures.

Checkpoint Inhibitors: These drugs work by targeting molecules that serve as brakes on the immune response. By blocking these inhibitory molecules or, alternatively, activating stimulatory molecules, checkpoint inhibitors are designed to unleash or enhance pre-existing anti-cancer immune responses. Nivolumab (Opdivo): A PD-1 Antibody +/- Ipilimumab (Yervoy): A CTLA-4 Antibody, are currently being tested in clinical trials for patients with lymphoma.

Prognosis:

Survival rates for NHL vary widely, depending on the lymphoma type, stage, age of the patient, and other variables. According to the American Cancer Society, the overall 5-year relative survival rate for patients with non-Hodgkin’s lymphoma is 67% and the 10-year relative survival rate is 55%.

Advanced age, Stage III and IV, poor performance status and a raised LDH all predict for a poorer outcome.

Survival rates for patients with NHL have greatly improved since the early 1990s, especially for patients under age 45. Advances in treatment have contributed to this improvement.

References:

  • Zhang QY, Foucar K. Bone marrow involvement by Hodgkin and non-Hodgkin lymphomas. Hematol Oncol Clin North Am. 2009 Aug. 23(4):873-902.
  • Hsia CC, Howson-Jan K, Rizkalla KS. Hodgkin lymphoma with cutaneous involvement. Dermatol Online J. 2009 May 15. 15(5):5.
  • Sanjay Vinjamaram, MD, MPH Non-Hodgkin Lymphoma: Practice Essentials, Background, Pathophysiology http://emedicine.medscape.com/article/203399-overview
  • Carol S. Portlock, MD. Non-Hodgkin Lymphomas – Hematology and Oncology – Merck Manuals Professional Edition http://www.merckmanuals.com/professional/hematology-and-oncology/lymphomas/non-hodgkin-lymphomas
  • DR P. Marazzi clinical photo of the neck of a patient with a non-Hodgkin’s type lymphoma https://www.sciencephoto.com/media/253181/view
  • Bigoni R, Negrini M, Veronese ML, et al: Characterization of t(11;14) translocation in mantle cell lymphoma by fluorescent in situ hybridization. Oncogene 13:797-802, 1996.
  • Mac Manus MP, Rainer Bowie CA, Hoppe RT. What is the prognosis for patients who relapse after primary radiation therapy for early-stage low-grade follicular lymphoma?. Int J Radiat Oncol Biol Phys. 1998 Sep 1. 42(2):365-71.
  • Rummel MJ, Niederle N, Maschmeyer G, Banat GA, etc. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013 Feb 19.
  • Czuczman MS, Rummel MJ. Clinical Roundtable Monograph: recent advances in NHL. Highlights from the 51st ASH Annual Meeting and Exposition, December 5-8, 2009, New Orleans, Louisiana. Clin Adv Hematol Oncol. 2010 Feb. 8(2):A1-11.
  • Barta SK, Li H, Hochster HS, Hong F, Weller E, Gascoyne RD, et al. Randomized phase 3 study in low-grade lymphoma comparing maintenance anti-CD20 antibody with observation after induction therapy: A trial of the ECOG-ACRIN Cancer Research Group (E1496). Cancer. 2016 Jun 28.
  • Goy A, Bernstein SH, Kahl BS, et al. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Ann Oncol. 2009 Mar. 20(3):520-5.
  • Malik SM, Liu K, Qiang X, Sridhara R, Tang S, McGuinn WD Jr, et al. Folotyn (pralatrexate injection) for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma: U.S. Food and Drug Administration drug approval summary. Clin Cancer Res. 2010 Oct 15. 16(20):4921-7.
  • Piekarz RL, Frye R, Prince HM, Kirschbaum MH, Zain J, Allen SL, et al. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood. 2011 Jun 2. 117(22):5827-34.
  • Salvatorelli E, Menna P, Paz OG, et al. The novel anthracenedione, pixantrone, lacks redox activity and inhibits doxorubicinol formation in human myocardium: insight to explain the cardiac safety of pixantrone in doxorubicin-treated patients. J Pharmacol Exp Ther. 2013;344:467–478.
  • University of Maryland Medical Center, Non-Hodgkin’s lymphoma, Prognosis, http://umm.edu/health/medical/reports/articles/nonhodgkins-lymphoma, Accessed: March 2013.

Leave a Reply

Your email address will not be published. Required fields are marked *